Fibroblast activation protein inhibitor compounds and methods

Details Fibroblast activation protein inhibitor compounds and methods Fibroblast activation protein inhibitor compounds and methods

2008-07-15

2008-07-15

Saeed, Kamal (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S423000

Reexamination Certificate

active

11437182

ABSTRACT:
Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

REFERENCES:
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5288707 (1994-02-01), Metternich
patent: 5574017 (1996-11-01), Gutheil
patent: 6355614 (2002-03-01), Wallner
patent: 6613879 (2003-09-01), Firestone et al.
patent: 6825169 (2004-11-01), Bachovchin et al.
patent: 6911467 (2005-06-01), Evans
patent: 2002/0155565 (2002-10-01), Garin-Chesa et al.
patent: 2003/0055052 (2003-03-01), Peters et al.
patent: 2003/0158114 (2003-08-01), Wallner et al.
patent: 2003/0211979 (2003-11-01), Blech et al.
patent: 2003/0232742 (2003-12-01), Peters et al.
patent: 2004/0229820 (2004-11-01), Bachovchin et al.
patent: 2006/0089312 (2006-04-01), Bachovchin et al.
patent: WO 93/08259 (1993-04-01), None
patent: WO 93/10127 (1993-05-01), None
patent: WO 03/092605 (2003-11-01), None
patent: WO 2005/047297 (2005-05-01), None
patent: WO2007005991 (2005-07-01), None
http://en.wikipedia.org/wiki/Racemic—mixture (1 page).
Bachovchin et al., “inhibition of IgA1 proteinases fromNeisseria gonorrhoeaeandHmophilus influenzaeby peptide prolyl boronic acids”, The Journal of Biol. Chem., 1990, 265, 3738-3743.
http://en.wikipedia.org/wiki/Amino—acid (11 pages).
http://en.wikipedia.org/wiki/EDTA (6 pages).
Lloyd-Williams et al., caplus an 1997:43089 (1 page).
Hu et al., “Synthesis and structure-activity relationship of n-alikyl gly-boro-pro inhibitors of dpp4, fap and dpp7”, Bioorg. Med Chem Lett, 15, 2005, 4239-4242.
Tran et al., “Synthesis and structure-activity relationship of n-acyl-gly-n-acyl-sar and n-blocked-boropro inhibitors of fap, dpp4, and pop”, Bioorg. & Med Chem Lett, 17, 2007, 1438-1442.
Megard et al., “A co-culture based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation”, Brain Research, 927, 2002, 153-167.
Cheng et al., “Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model”, Cancer Research, 62, 4767-4772.
Edosada et al, “Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificty”, The Journal of Biol. Chem, 2006, 281, 7437-7444.
Venalailen et al., “Binding kinetics and duration of in vivo action of novel prolyl oligopedtidase inhibitors”, Biochem. Pharm, 71, 2006, 683-692.
Zips et al, “new anticancer agents: in vitro and in vivo”, in vivo, 2005, 19, 1-7.
fact sheet Alzheimers association, 2 pages.
http://www.mayoclinic.com/health/alzheimers-disease/DS00161/DSECTION=3, (2 pages).
http://www.medindia.net/patients/patientinfo/Alzheimers—treatment.htm.
http://en.wikipedia.org/wiki/Lanthionine (2 pages).
Kelly et al., “Immunosuppressive Boronic Acid Dipeptides: Correlation between Conformation and Activity”J. Am. Chem. Soc. 115:12637-12638 (1993).
Adams et al., “PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism”Cancer Research64:5471-5480 (Aug. 1, 2004).
Aertgeerts et al., “Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha”Journal of Biological Chemistry280(20):19441-19444 (May 20, 2005).
Bachovchin et al., “Inhibition of IgA1 proteinases fromNeisseria gonorrhoeaeandHemophilus influenzaeby peptide prolyl boronic acids”J Biol Chem. 267(7):3738-3743 (Mar. 5, 1990).
Cheng et al., “Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth”Mol Cancer Ther. 4:351-360 (2005).
Coutts et al., “Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides”J Med Chem. 39(10):2087-2094 (May 10, 1996).
Coutts et al., “Two efficient Methods For The Cleavage Of Pinanediol Boronate Esters Yielding The Free Boronic Acids”Tetrahedron Letters35(29):5109-5112 (1994).
Edosada et al., “Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity”J Biol Chem. 281(11):7437-7444 (Mar. 17, 2006).
Flentke et al., “Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function”Proc Natl Acad Sci U S A. 88(4):1556-1559 (Feb. 15, 1991).
Gao et al., “Direct Selection for Catalysis from Combinatorial Antibody Libraries Using a Boronic Acid Probe: Primary Amide Bond Hydrolysis”J. Am. Chem. Soc. 120(10):2211-2217 (Mar. 18, 1998).
Gibson et al., “A Practical Synthesis of L-Valyl-pyrrolidine-(2R)-boronic Acid: Efficient Recycling of the Costly Chiral Auxiliary (+)-Pinanediol”Organic Process Research&Development6:814-816 (2002).
Hu et al., “Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7”Bioorg Med Chem Lett. 15(19):4239-4242 (Oct. 1, 2005).
Jones et al., “Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies”Blood102(5):1641-1648 (Sep. 1, 2003).
Kelly et al., “The Efficient Synthesis and Simple Resolution of a Prolineboronate Ester Suitable for Enzyme-Inhibition Studies”Tetrahedron Letters49(5):1009-1016 (1993).
Rosenblum et al., “Prolyl peptidases: a serine protease subfamily with high potential for drug discovery”Curr Opin Chem Biol. 7(4):496-504 (Aug. 2003).
Shreder et al., “Boro-norleucine as a P1 residue for the design of selective and potent DPP7 inhibitors”Bioorg Med Chem Lett. 15(19):4256-4260 (Oct. 1, 2005).
Snow et al., “Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Indentification of a Cyclic Species Containing a B-N Bond”J. Am. Chem. Soc. 116:10860-10869 (1994).
Venalainen et al., “Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors”Biochem Pharmacol. 71(5):683-692 (Feb. 28, 2006).

Affiliated with

Also associated with

Rating

Fibroblast activation protein inhibitor compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fibroblast activation protein inhibitor compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibroblast activation protein inhibitor compounds and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3925568